Abstract
Hematologic malignancies are a heterogeneous group of diseases with differing clinical manifestations, disease course, response to therapy, and long-term outcome. More intensive therapies are also being extended to older age groups and to patients with significant comorbidities, which were traditionally excluded from such treatment. These intensive treatment approaches are associated with multiple complications; infections from a wide variety of pathogenic and opportunistic organisms being amongst the commonest and the most serious. Infections affect quality of life, delay potentially saving chemotherapy and pose a substantial burden for the health care system and remain an important cause of death. In this chapter we outline the common immune defects and associated infections frequently seen in patients with hematologic malignancies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Burnett AK. Acute myeloid leukemia: treatment of adults under 60 years. Rev Clin Exp Hematol. 2002;6(1):26–45; discussion 86–7.
Koistinen P et al. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): the nationwide AML-92 study by the Finnish Leukaemia Group. Eur J Haematol. 2007;78(6):477–86.
Chamilos G et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica. 2006;91(7):986–9.
Elonen E et al. Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group. Leukemia. 1998;12(7):1041–8.
Castaigne S et al. Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004;104(8):2467–74.
Hersh EM et al. Causes of death in acute leukemia: a ten-year study of 414 patients from 1954–1963. JAMA. 1965;193:105–9.
Caggiano V et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916–24.
Dale DC. The benefits of haematopoietic growth factors in the management of gynaecological oncology. Eur J Gynaecol Oncol. 2004;25(2):133–44.
Darmon M et al. Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients. Intensive Care Med. 2002;28(12):1775–80.
Kuderer NM et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66.
Talcott JA et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol. 1992;10(2):316–22.
Rossini F. Prognosis of infections in elderly patients with haematological diseases. Support Care Cancer. 1996;4(1):46–50.
Elting LS et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25(2):247–59.
Malik I, Hussain M, Yousuf H. Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies. J Infect. 2001;42(2):120–5.
Styrt B. Infection associated with asplenia: risks, mechanisms, and prevention. Am J Med. 1990;88(5N):33N–42.
Norris RP, Vergis EN, Yu VL. Overwhelming postsplenectomy infection: a critical review of etiologic pathogens and management. Infect Med. 1996;13:779–83.
Torres HA et al. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica. 2007;92(9):1216–23.
Zuccotti G, Sepkowitz KA. Management of infection in oncology patients: infection control. In: Wingard JR, Bowden RA, editors. Infections in oncology patients. Philadelphia, PA: Martin Dunitz; 2003.
Hachem RY et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer. 2004;101(7):1594–600.
Uzun O et al. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis. 2001;32(12):1713–7.
Anaissie EJ et al. Predictors of adverse outcome in cancer patients with candidemia. Am J Med. 1998;104(3):238–45.
Bodey GP et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328–40.
Pizzo PA. Fever in immunocompromised patients. N Engl J Med. 1999;341(12):893–900.
Rolston KV et al. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients. Int J Infect Dis. 2006;10(3):223–30.
Safdar A et al. Changing trends in etiology of bacteremia in patients with cancer. Eur J Clin Microbiol Infect Dis. 2006;25(8):522–6.
Donowitz GR, et al. Infections in the neutropenic patient – new views of an old problem. Hematology Am Soc Hematol Educ Program. 2001;113–39.
Lautenbach E et al. Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins. Clin Infect Dis. 2003;36(4):440–6.
Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136(11):834–44.
Gonzalez-Barca E et al. Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis. 1999;18(8):539–44.
Pagano L et al. Bacteremia in patients with hematological malignancies. Analysis of risk factors, etiological agents and prognostic indicators. Haematologica. 1997;82(4):415–9.
Norgaard M et al. Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect. 2006;12(3):217–23.
Bochud PY et al. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18(1):25–31.
Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992;14(6):1201–17.
Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 2002;34(11):1524–9.
Pizzo PA et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72(1):101–11.
Hughes WT et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. 1997;25(3):551–73.
Edmond MB et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29(2):239–44.
Pfaller MA et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001;39(9):3254–9.
Anttila VJ et al. Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis. 1997;24(3):375–80.
Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis. 2002;21(3):161–72.
Pagano L et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–75.
Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am. 1996;10(2):365–400.
Roden MM et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53.
Kontoyiannis DP et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350–60.
Chandrasekar PH. Fungi other than Candida and Aspergillus. In: Bowden RA, editor. Infections in oncology patients. Philadelphia, PA: Martin Dunitz; 2003.
Bogomolski-Yahalom V, Matzner Y. Disorders of neutrophil function. Blood Rev. 1995;9(3):183–90.
Serbina NV et al. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol. 2008;26:421–52.
Wade JC. Viral infections in patients with hematological malignancies. Hematology Am Soc Hematol Educ Program. 2006;368–74.
Huang H et al. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin’s lymphoma single institution experience. Expert Opin Pharmacother. 2009;10(15):2399–406.
Uchiyama M, Tamai Y, Ikeda T. Low-dose acyclovir against reactivation of varicella zoster virus after unrelated cord blood transplantation. Int J Infect Dis. 2009;14(5):e451–2.
Waecker Jr NJ et al. Nosocomial transmission of Mycobacterium bovis bacille Calmette-Guerin to children receiving cancer therapy and to their health care providers. Clin Infect Dis. 2000;30(2):356–62.
Pei SN et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2009;89(3):255–62.
Gabriel DA et al. The effect of oral mucositis on morbidity and mortality in bone marrow transplant. Semin Oncol. 2003;30(6 Suppl 18):76–83.
Sonis ST. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002;13(5):380–9.
Sonis ST et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl):1995–2025.
Schimpff SC et al. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med. 1972;77(5):707–14.
Weinstock DM et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007;13(5):615–21.
David DS et al. Visceral varicella-zoster after bone marrow transplantation: report of a case series and review of the literature. Am J Gastroenterol. 1998;93(5):810–3.
Ravandi F, Anaissie E, O’Brien S. Infections in chronic leukemias and other hematological malignancies. In: Wingard JR, Bowden RA, editors. Infections in oncology patients. Philadelphia, PA: Martin Dunitz; 2003.
Molica S, Levato D, Levato L. Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica. 1993;78(6):374–7.
Tam CS et al. A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer. 2004;101(9):2042–9.
Anaissie EJ et al. Infection in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129(7):559–66.
Lungman P. Viral infections: current diagnosis and treatment. Hematol J. 2004;5:S63–8.
Sandherr M et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol. 2006;17(7):1051–9.
O’Brien SM et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19(5):1414–20.
Cavalli-Bjorkman N et al. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia. Med Oncol. 2002;19(4):277–80.
Kennedy B, Hillmen P. Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL. Med Oncol. 2002;19(Suppl):S49–55.
Rai KR et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20(18):3891–7.
Laurenti L et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica. 2004;89(10):1248–52.
Rawstron AC et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood. 2004;103(6):2027–31.
Rieger K et al. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia – change of regimen needed? Leuk Lymphoma. 2004;45(2):345–9.
Wendtner CM et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004;18(6):1093–101.
Lin TS et al. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia. 2005;19(7):1207–10.
Lundin J et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100(3):768–73.
Keating MJ et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10):3554–61.
Keating MJ et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92(4):1165–71.
Keating MJ et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079–88.
Tam C et al. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica. 2005;90(5):700–2.
Blade, J, Rosinol L. Complications of multiple myeloma. Hematol Oncol Clin North Am. 2007;21(6):1231–46, xi.
Hargreaves RM et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol. 1995;48(3):260–6.
Savage DG, Lindenbaum J, Garrett TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med. 1982;96(1):47–50.
San Miguel JF et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.
Lortholary O et al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myelome. Clin Infect Dis. 2000;30(1):41–6.
Fisher RI et al. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin’s disease. Ann Intern Med. 1980;92(5):595–9.
Dalton JA et al. Cutaneous T-cell lymphoma. Int J Dermatol. 1997;36(11):801–9.
Posner LE et al. Septicemic complications of the cutaneous T-cell lymphomas. Am J Med. 1981;71(2):210–6.
Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and Sezary syndrome. JAMA. 1992;267(10):1354–8.
Thursky KA et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol. 2006;132(1):3–12.
National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prevention and treatment of cancer related infections (v.2.2009). Jenkintown, PA: NCCN; 2009.
Marshall BG et al. Increased inflammatory cytokines and new collagen formation in cutaneous tuberculous and sarcoidosis. Thorax. 1996;51(12):1253–61.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Papanicolaou, G., Mehta, J. (2011). Infections in Patients with Hematologic Malignancies. In: Safdar, A. (eds) Principles and Practice of Cancer Infectious Diseases. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-644-3_3
Download citation
DOI: https://doi.org/10.1007/978-1-60761-644-3_3
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-643-6
Online ISBN: 978-1-60761-644-3
eBook Packages: MedicineMedicine (R0)